Morinaga Milk Reveals Major Breakthroughs in a ‘Bifidobacteria Training’ Program With Professional Footballer Yuto Nagatomo
Morinaga Milk Industry Co., Ltd. (TOKYO:2264), a pioneer in bifidobacteria and gut microbiota research, reveals that its collaborative ‘Bifidobacteria Training’ project (launched in June 2020) helped professional athlete Yuto Nagatomo improve his gut microbiota. Nagatomo stayed on the program for a full year, and has been outspoken about the changes in his gut microbiota that not only improved his digestive system, but also his physical condition.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210831005058/en/
In recent crosstalk, footballer Yuto Nagatomo speaks passionately about his full year on the ‘Bifidobacteria Training’ program. “My condition improved because I stayed with it.” “Bifidobacteria ‘saved me’”, he shared. (Graphic: Business Wire)
About the ‘Bifidobacteria Training’ program
The program encourages participants to incorporate bifidobacteria into their existing knowledge, diet, and physical and mental health regimens with the aim of improving the environment of the large intestine through input from inside and outside the body.
The ‘Bifidobacteria Training’ program website offers a wealth of information not available elsewhere, including varied content on knowledge, diet, exercise, and mental health, and a profile of Yuto Nagatomo’s gut microbiota shaped by his consistent intake of bifidobacteria since 2020.
1. Overview of Report on ‘Bifidobacteria Training’ CROSS-TALK 2020-2021
Footballer Yuto Nagatomo started taking bifidobacteria in July 2020, during the offseason. He later signed with a French (Ligue 1) team, and his condition suffered as he attempted to adapt to an unfamiliar living environment. However, his digestive system steadily regained its balance thanks to his persistence with the ‘Bifidobacteria Training’ program. Our analysis of his gut microbiota revealed inconsistency immediately after his move to France, followed by certain changes that suggested a strong connection between his enteric bacteria and his physical condition.
Nagatomo recognized the changes as they were occurring. “My condition improved because I stayed with the ‘Bifidobacteria Training’ program every day,” he said. “Even on days I couldn’t sleep, both my digestive system and my physical condition were stable.” He also noted that his recovery speed had improved, and identified the source without uncertainty. “[Bifidobacteria] saved me.” His condition and performance on the field continuously improved. “I’m so much more confident now that I have the final piece of the puzzle in my goal to represent Japan in the 2022 World Cup.”
He reflected on his full year on the ‘Bifidobacteria Training’ program, noting that staying with it was important, yet not all that burdensome. “[Staying with the program] was everything for my gut microbiota,” he said in a nod to a Japanese adage about the value of persistence in sport. “It helped me so much. I’m grateful for the support.”
2. Changes in Yuto Nagatomo’s gut microbiota on the ‘Bifidobacteria Training’ program
Dr. Toshitaka Odamaki, Manager of the Microbiota Research Department at the Next Generation Science Institute of Morinaga Milk, analyzed Nagatomo’s gut microbiota over the roughly seven months in which he took bifidobacteria. “The balance of enteric bacteria shifted substantially after [Nagatomo] moved from Japan to France, but his intake of bifidobacteria and balanced meals created a new balance that stabilized in December,” Dr. Odamaki said, also confirming the disappearance of the harmful bacteria may be associated with the cause of Nagatomo’s illnesses. “The analysis showed increases in good bacteria such as bifidobacteria and butyrate-producing bacteria following his persistence with the ‘Bifidobacteria Training’ program.” Dr. Odamaki also noted that Nagatomo had a growing population of bacteria that is linked to the performance of professional athletes.”The changes in gut microbiota could be a factor behind Nagatomo’s sense that his condition improved.”
“This is the first experience to track the detailed changes in an individual’s gut microbial composition,” Dr. Odamaki said. “Our analysis illustrated a strong connection between tangible feelings and enteric bacteria, which are normally hidden from us, a significant finding among Morinaga Milk’s research.”
About professional footballer Yuto Nagatomo
Born in Ehime Prefecture, Japan in 1986. Made his official J. League debut with FC Tokyo in 2008. Invited to play on the Japanese national team for the first time in May 2008, and appeared in the Beijing Olympics in August of that year. Played every minute of Japan’s four games in the 2010 World Cup in South Africa, signed with Cesena of Serie A (Italy) in July of that year. Signed with the vaunted Inter Milan in January 2011. Played every minute of Japan’s games in the 2014 World Cup in Brazil. Joined Galatasaray S.K. of the TFF 1. Lig (Turkey) on loan in 2018. Advanced to the finals for the first time at the 2018 World Cup in Russia. Joined Galatasaray S.K. on a permanent deal in 2019, and won two consecutive Süper Lig titles and two Turkish Cup trophies. Signed with Olympique de Marseilles of Ligue 1 (France) on August 31, 2020. Developed original exercise methods incorporating elements of stretching, yoga, and core training, worked with a personal chef and physician to develop a fat-adaptation diet, and more. With a style of examining his body from the inside and outside, he continues to maintain a high level of athletic performance, and has declared his goal to represent Japan in the 2022 World Cup.
About Morinaga Milk’s initiatives with Yuto Nagatomo
Morinaga Milk sensed Yuto Nagatomo’s dedication to constant improvement as a professional athlete, evident in his commitment to physical fitness, diet, and other facets of health within his control. We heard of his concern about his digestive system suffering during extended stays outside Japan despite unflagging self-control, and wanted to apply our findings from many years of research to try to improve his intestinal environment and help him continue to evolve as an athlete from the inside out.
Additionally, “nurturing the next generation” is one of the themes of ESG-focused management, a basic policy from our Medium-Term Business Plan. We aim to teach people the importance of food for maintaining healthy bodies and minds, while also helping them grow as people with positive attributes like agency, autonomy, and motivation to take on challenges, all in an effort to nurture the next generation in order to create a sustainable society.
These goals resonate with Nagatomo, who for his part has established the Yuto Nagatomo Football Academy (YNFA), founded Cuore Inc. with the aim of using his influence as an athlete to solve health problems around the world, and devoted energy to activities in support of single-parent families.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Morinaga Milk Industry Co., Ltd.
Investor& Public Relations Department
Ryo Mikami/Mitsunori Watanabe
Junichi Minami /Chyn Boon Wong
Morinaga Milk website: https://www.morinagamilk.co.jp/english/
Morinaga Probiotics Center website: https://morinagamilk-ingredients.com/
Morinaga Probiotics Center LinkedIn: https://www.linkedin.com/company/morinaga-probiotics-center
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)18.9.2021 15:34:00 CEST | Press release
Celltrion Group announced that the Korean Ministry of Food and Drug Safety (MFDS) approved regdanvimab (CT-P59), a monoclonal antibody treatment for COVID-19 for the extended use in elderly patients aged 50 years and over, or with at least one underlying medical condition (the obese, cardiovascular disease, chronic lung disease, diabetes, chronic kidney disease, chronic liver disease, and patients with immunosuppressive agents) with mild symptoms of COVID-19, and adult patients with moderate symptoms of COVID-19. This marks the first time a monoclonal antibody treatment for COVID-19 has received a full approval to treat patients with COVID-19 from the Korean MFDS. In February, the Korean MFDS granted a Conditional Marketing Authorisation (CMA) for the emergency use of regdanvimab (CT-P59) and allowed the use of CT-P59 in adult patients aged 60 years and over, or with at least one underlying medical condition (cardiovascular, chronic respiratory disease, diabetes, high blood pressure) w
Ipsen: ESMO 2021: Cabometyx ® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer18.9.2021 06:30:00 CEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced presentation of new analyses at the European Society for Medical Oncology (ESMO) Congress 2021 across different forms of cancer for people treated with Cabometyx® (cabozantinib). Of note, the final analysis of the pivotal Phase III COSMIC-311 trial (Abstract LBA67) will be presented, with Cabometyx demonstrating a clinically meaningful, sustained efficacy benefit versus placebo in people living with previously treated radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). With a median follow-up of 10.1 months, Cabometyx continued to demonstrate superior median progression-free survival (mPFS) with a reduction in the risk of disease progression or death of 78% versus placebo (hazard ratio [HR]: 0.22, 96% confidence interval [CI]: 0.15-0.32; p<0.0001).1 This final analysis is consistent with data from the interim analysis, presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021
Unifrax Hosts Groundbreaking Ceremony for SiFAB™ Manufacturing Line17.9.2021 20:46:00 CEST | Press release
Today, Unifrax, a leading manufacturer of high-performance specialty materials, held a ceremonial event celebrating its first large-scale SiFAB™ Silicon Fiber Anode Battery Technology manufacturing line, which is currently under construction at the company’s north central Indiana facility. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005495/en/ Unifrax team celebrates SiFAB groundbreaking at New Carlisle plant. (Photo: Business Wire) The event recognized Unifrax’s ongoing partnership with the State of Indiana and St. Joseph County, along with SiFAB’s continued progress. Unifrax executives, along with the SiFAB manufacturing team and local and state government officials, kicked off the ceremony at 10 a.m. EDT at the New Carlisle, IN plant, with remarks by John Dandolph, president and CEO, Unifrax. “Through the support of the State of Indiana and St. Joseph County, we have the ability to leverage our existing New Carli
Prince William announces 15 Finalists for inaugural year of the £50 million Earthshot Prize17.9.2021 19:01:00 CEST | Press release
The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet. Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet. “I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.” Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Li
Wipro Announces Co-innovation Space with Google Cloud17.9.2021 15:32:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced the launch of the Wipro-Google Cloud Innovation Arena in Bangalore, India. This cloud collaboration space will provide in-house technical expertise, ensure seamless cloud adoption, and accelerate innovation to drive business transformation for customers. By combining the expertise and resources of Wipro FullStride Cloud Services and Google Cloud, this jointly developed innovation center will offer a unique combination of people, processes, and platforms that will collectively create a futuristic experience for customers globally. This state-of-the-art arena will showcase the talent, tools and best practices required to develop and deploy applications on Google Cloud. Jason Eichenholz, Senior Vice President, Global Head of Ecosystems & Partnerships, Wipro Limited said, “We are excited to strengthen our partnership with Google Clou
Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat17.9.2021 15:00:00 CEST | Press release
Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced today that ReVamp, an upcoming multiplayer social deception game, will launch soon in select markets exclusively for Snapchat. The vampire-themed game will be the first social deception title on Snapchat, giving Snapchatters their first chance to sink their teeth into this popular genre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210917005012/en/ Zynga Announces ReVamp, the First Multiplayer Social Deception Game For Snapchat (Graphic: Business Wire) ReVamp is a real-time multiplayer imposter game where players aim to reveal who the vampire player is among their group of friends while they renovate the rooms of an old mansion. In the game, human players must complete renovation tasks, such as demolition and building, to improve their chances of survival while identifying and defeating the vampire during the voting phase. Vampire players mu
BeiGene Receives Positive CHMP Opinion for BRUKINSA ® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia17.9.2021 14:00:00 CEST | Press release
BeiGene (NASDAQ: BGNE; HKEX: 06160) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of BRUKINSA (zanubrutinib) for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy. “Bruton’s tyrosine kinase (BTK) inhibitors have emerged as a promising treatment for WM, yet treatment discontinuation due to lack of response or side effects remains a concern,” said Prof. Christian Buske, Medical Director at the University Hospital Ulm, Germany, and a trial investigator of the ASPEN study. “The ASPEN trial demonstrated that BRUKINSA provided deep and durable responses and offered substantial improvements in safety and tolerability over standard therapy. Patients in Europe with WM may soon have a new treatment option that can offer improved outcomes.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom